Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Medullary Thyroid Cancer Pipeline Review, H2 2016 - Companies & Molecules by Phase III, Phase II & Pre-Clinical Stage - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H2 2016" drug pipelines to their offering.

'Medullary Thyroid Cancer - Pipeline Review, H2 2016'; Medullary Thyroid Cancer pipeline therapeutics constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Medullary Thyroid Cancer Medullary thyroid cancer (MTC) is a form of thyroid cancer that originates from the parafollicular cells of the thyroid gland. The parafollicular cells secrete the hormone calcitonin. The calcitonin hormone works together with the parathyroid hormone (a protein hormone secreted by parathyroid cells) to regulate calcium levels in the body.

The symptoms associated with MTC are similar to other forms of thyroid cancer. They include a visible lump (nodule), the sensation of a lump with swallowing, hoarseness or enlarged lymph nodes that do not go away. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

The report 'Medullary Thyroid Cancer - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Medullary Thyroid Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Medullary Thyroid Cancer - Overview
  5. Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis
  6. Medullary Thyroid Cancer - Therapeutics under Development by Companies
  7. Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Medullary Thyroid Cancer Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Medullary Thyroid Cancer - Products under Development by Companies
  13. Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes
  14. Medullary Thyroid Cancer - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Advenchen Laboratories, LLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Hutchison MediPharma Limited
  • Immunomedics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Pfizer Inc.

For more information about this drug pipelines report visit

Related Topics: Oncology Drugs , Thyroid Cancer Drugs

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.